Company intelligence / Profile preview
Kivu Bioscience
- Ownership
- Private
- Development stage
- Preclinical
Overview
Kivu Bioscience is advancing a pipeline of next-generation antibody-drug conjugates using proprietary site-specific conjugation technologies designed to improve the stability, homogeneity, and therapeutic window of ADC therapies. Their approach aims to reduce off-target toxicity and address limitations seen with current marketed ADCs. The company has raised $92 million Series A financing led by Novo Holdings to bring its first two lead candidates into clinical trials starting in 2025. Early data suggest superior construct stability compared to prior generations.
- Therapeutic areas
- OncologyOther
- Modalities
- Antibody-drug conjugates (ADCs)Topo1i-based ADCs (topoisomerase I inhibitor payloads)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Kivu Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kivu Bioscience.